Latest Ratios: P/E Ratio -5.7x · EV/EBITDA N/A · ROE -90.3%. (1996–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $510M | $287M | $106M | $215M | $164M | $708M | $600M | — | — | — | — |
| Enterprise Value | $499M | $276M | $-15144639 | $146M | $109M | $635M | $573M | — | — | — | — |
| P/E Ratio → | -5.71 | — | — | — | — | — | — | — | — | — | — |
| P/S Ratio | 911.73 | 513.72 | 2.45 | 8.46 | 9.27 | 57.06 | 109.45 | — | — | — | — |
| P/B Ratio | 8.18 | 4.61 | 0.79 | 9.77 | 7.41 | 83.08 | 66.20 | — | — | — | — |
| P/FCF | — | — | — | — | — | 95.91 | — | — | — | — | — |
| P/OCF | — | — | — | — | — | 77.11 | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | 493.83 | -0.35 | 5.77 | 6.19 | 51.14 | 104.50 | — | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | 85.97 | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 61.5% | 61.5% | 72.7% | 59.3% | 37.8% | 39.9% | 31.3% | 100.0% | — | -49543.8% | -1031.3% |
| Operating Margin | -16056.0% | -16056.0% | -146.4% | -195.5% | -281.9% | -369.0% | -654.3% | -9317.2% | — | -89943.8% | -1546.2% |
| Net Profit Margin | -15851.9% | -15851.9% | -104.7% | -170.5% | -232.4% | -317.4% | -594.0% | -8025.4% | — | -10112.5% | -1096.1% |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -90.3% | -90.3% | -58.1% | -196.4% | -268.2% | -448.2% | -217.2% | -70.0% | -42.1% | -3.0% | -14.7% |
| ROA | -53.0% | -53.0% | -28.1% | -38.1% | -40.3% | -43.3% | -49.3% | -46.1% | -39.2% | -2.9% | -14.4% |
| ROIC | -210.4% | -210.4% | -370.7% | — | — | — | — | -160.5% | -133.2% | -87.1% | -75.4% |
| ROCE | -59.1% | -59.1% | -44.8% | -54.3% | -59.7% | -64.8% | -74.0% | -63.6% | -47.1% | -27.0% | -20.8% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.02 | 0.04 | 0.01 | — | — | — |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.18 | -0.90 | -3.11 | -2.46 | -8.61 | -2.99 | -0.63 | -0.61 | -0.82 | -0.72 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | -9.94 | — | -7.70 | — | — | — |
| Interest Coverage | — | — | — | -1478.71 | -1058.71 | -5731.00 | -2251.56 | -692.03 | — | -250.67 | — |
Net cash position: cash ($11M) exceeds total debt ($160000)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 8.72 | 8.72 | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 7.70 | 17.14 | 26.09 |
| Quick Ratio | 8.72 | 8.72 | 11.14 | 4.62 | 4.41 | 5.69 | 2.99 | 3.88 | 8.34 | 18.08 | 27.95 |
| Cash Ratio | 6.25 | 6.25 | 8.76 | 3.08 | 3.24 | 4.85 | 1.46 | 3.47 | 6.93 | 16.21 | 24.23 |
| Asset Turnover | — | 0.00 | 0.21 | 0.21 | 0.16 | 0.13 | 0.06 | 0.01 | — | 0.00 | 0.01 |
| Inventory Turnover | — | — | — | — | — | — | — | — | — | — | — |
| Days Sales Outstanding | — | 16071.75 | 227.04 | 344.89 | 18.92 | 9.73 | 1952.31 | 5.98 | — | — | 383.96 |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 | FY 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | 1.0% | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — | — | — |
| Shares Outstanding | — | $47M | $15M | $12M | $11M | $30M | $27M | $25M | $23M | $23M | $23M |
Imminent liquidity and dilution
According to current market data, Silence Therapeutics trades at a price-to-sales ratio of 856.80, a figure that appears detached from fundamental performance and instead reflects investor anticipation of future clinical milestones rather than any current ability to generate sustainable, recurring revenue from its proprietary mRNAi GOLD platform.
The extreme P/S multiple suggests that the market is pricing the company as a high-stakes option on its cardiovascular pipeline rather than a traditional operating entity. Investors should monitor whether this valuation can be sustained as the company approaches a likely dilutive capital raise, which would reset the denominator of these valuation metrics.
As reported in quarterly financial statements, the company's ROIC has fluctuated wildly, reaching a low of -159.3% in 2024Q2, which underscores the structural difficulty of generating positive returns on invested capital while the firm remains in a pre-commercial, high-expenditure phase of its clinical development lifecycle.
The persistent negative ROIC indicates that every dollar of capital deployed is currently destroying shareholder value rather than compounding it. This trend warrants further investigation into whether the company's chemical platform can eventually achieve the scale necessary to offset the massive R&D overhead currently suppressing all return metrics.
Based on recent filings, the company's DSO has reached extreme levels, such as the 63,310 figure reported in 2025Q4, which suggests that the firm's revenue recognition process is highly disconnected from actual cash collection cycles typical of a standard commercial enterprise operating in the biotechnology sector.
These erratic efficiency ratios are symptomatic of a milestone-driven revenue model where accounting recognition often precedes cash receipt by several quarters. Analysts should view these figures as artifacts of IFRS 15 compliance rather than indicators of operational prowess or effective management of customer payment terms.
As indicated by the company's reported figures, the current ratio has remained elevated due to high cash balances, yet the rapid depletion of these assets from 12.82 in 2024Q1 to 9.83 in 2026Q1 suggests a narrowing window for the firm to achieve self-sustaining clinical milestones.
While the current ratio appears superficially healthy, it masks the reality that the company is burning through its primary liquidity source to fund late-stage trials. The lack of debt provides a clean balance sheet, but it also limits the company's ability to leverage its assets to bridge the current funding gap.
The most commonly misapplied ratio for Silence Therapeutics is the P/E multiple, which is fundamentally inappropriate for a pre-commercial biotech firm that lacks consistent earnings and relies entirely on milestone-based revenue recognition that does not correlate with the actual cash-generating capacity of the underlying mRNAi platform.
Investors should instead focus on the cash runway and the net burn rate, as these metrics provide a more accurate assessment of the company's survival probability. Using P/E to value a firm with negative margins and non-recurring revenue obscures the reality that the company is currently a capital-consuming entity.
Includes 30+ ratios · 30 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying SLN stock.
Silence Therapeutics plc's current P/E ratio is -5.7x. This places it at the 50th percentile of its historical range.
Silence Therapeutics plc's return on equity (ROE) is -90.3%. The historical average is -72.8%.
Based on historical data, Silence Therapeutics plc is trading at a P/E of -5.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Silence Therapeutics plc has 61.5% gross margin and -16056.0% operating margin.